Evidence map›Paper›PMID 40829518›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2025

A primary human Gut/Liver microphysiological system to estimate human oral bioavailability.

Yassen Abbas, Morné van Wyk, Hailey Sze, James Christophi, Ashley A Spreen, Robert Jarrett Bliton, Elizabeth M Boazak, Tomasz Kostrzewski

Abstract read
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yassen AbbasCN Bio Innovations Ltd, Cambridge, United Kingdom. Electronic address: yassen.abbas@cn-bio.com.
Morné van WykCN Bio Innovations Ltd, Cambridge, United Kingdom.
Hailey SzeCN Bio Innovations Ltd, Cambridge, United Kingdom.
James ChristophiCN Bio Innovations Ltd, Cambridge, United Kingdom.
Ashley A SpreenAltis Biosystems, Durham, North Carolina.
Robert Jarrett BlitonAltis Biosystems, Durham, North Carolina.
Elizabeth M BoazakAltis Biosystems, Durham, North Carolina.
Tomasz KostrzewskiCN Bio Innovations Ltd, Cambridge, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral bioavailability is a crucial pharmacokinetic (PK) parameter optimized by drug developers working on new therapeutic compounds. The goal is to obtain adequate systemic exposure and to establish safe and effective therapeutic dosages. Critical to optimizing oral bioavailability is understanding a compound's susceptibility to first-pass metabolism, determined by the intricate relationship between gut absorption, metabolism, and hepatic metabolism. Efforts to model this relationship in vitro have led to the emergence of microphysiological systems (MPSs) that consist of multiple, fluidically linked organs. Here, we describe an MPS that links the gut and liver, capable of simulating both oral and intravenous dosing routes and is made up of entirely primary human cells: a gut barrier tissue comprised of an intestinal epithelial monolayer derived from the human jejunum, and a liver microtissue, derived from primary human hepatocytes. Functionality of gut and liver tissues is maintained in coculture enabling the PK investigation of oral compounds. We combine the primary Gut/Liver MPS with a mechanistic mathematical model to generate organ-specific PK parameters and estimate human oral bioavailability and its components: the fraction absorbed (F

Indexed as

Intestinal MucosaLiverAdministration, OralBiological AvailabilityCytochrome P-450 CYP3AHepatocytesHumansIntestinal AbsorptionJejunumMicrophysiological SystemsModels, BiologicalCytochrome P-450 CYP3ABioavailabilityGut liver microphysiological systemMechanistic modelingMicrophysiological systemOrgan-on-a-chip

Identifiers

PMID40829518
PMCPMC12597587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.